UFH Bolus with Tenecteplase: Yes, Administer Concurrently
Yes, an unfractionated heparin (UFH) bolus should be given concurrently with tenecteplase in adults with STEMI, using a weight-adjusted dose of 60 U/kg IV bolus (maximum 4,000 U) followed by an infusion of 12 U/kg/hour (maximum 1,000 U/hour), adjusted to maintain aPTT at 50-75 seconds for 48 hours. 1
Recommended Dosing Regimen
The 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines provide clear anticoagulation recommendations for fibrinolytic therapy 1:
Weight-adjusted UFH dosing:
- Initial bolus: 60 U/kg IV (maximum 4,000 U)
- Infusion: 12 U/kg/hour (maximum 1,000 U/hour)
- Duration: Minimum 48 hours, can continue longer at physician discretion
- Target aPTT: 50-75 seconds
This represents a more conservative, weight-adjusted approach compared to older fixed-dose regimens and is supported by the FDA label for tenecteplase, which describes the pivotal ASSENT-2 trial protocol 2.
Evidence Supporting Concurrent UFH Administration
Guideline-Based Rationale
The guidelines emphasize that parenteral anticoagulation is recommended before and after fibrinolytic therapy to reduce ischemic events 3. The premature discontinuation of anticoagulation is associated with rebound thrombin activity and reactivation of ischemic events, with greatest reinfarction risk in the first 4-8 hours after stopping anticoagulation 3.
Clinical Trial Evidence
The FDA label documents that in the ASSENT-2 trial (8,461 patients receiving tenecteplase), intravenous heparin was administered "as soon as possible" using a weight-stratified approach 2:
- Patients ≤67 kg: 4,000-unit bolus + 800 U/hour infusion
- Patients >67 kg: 5,000-unit bolus + 1,000 U/hour infusion
- Continued for 48-72 hours with aPTT maintained at 50-75 seconds
This regimen achieved 30-day mortality of 6.2% with intracranial hemorrhage rate of 0.9% 2.
Refined Dosing Strategy
Research evidence demonstrates that smaller dose, weight-adjusted heparin reduces bleeding without compromising efficacy 4. The ASSENT-3 trial used the refined regimen (60 U/kg bolus, maximum 4,000 U; 12 U/kg/hour infusion, maximum 1,000 U/hour) and showed:
- Similar mortality and intracranial hemorrhage rates compared to ASSENT-2
- Significantly less major bleeding (2.2% vs 4.7%, p<0.001)
- Less refractory ischemia (6.5% vs 8.6%, p<0.001)
This supports the current guideline recommendation for the lower, weight-adjusted dosing strategy 4.
Critical Timing Considerations
Administer the UFH bolus concurrently with tenecteplase - the evidence consistently shows heparin was given "as soon as possible" in the pivotal trials 2. Recent meta-analysis data, while focused on primary PCI patients, suggests UFH pretreatment may reduce coronary occlusion and mortality without increasing bleeding 5, 6, supporting early rather than delayed administration.
Common Pitfalls to Avoid
1. Excessive Heparin Dosing
Do not use the older fixed-dose regimens (5,000 U bolus for all patients >67 kg). The weight-adjusted approach with lower maximum doses reduces bleeding complications 4.
2. Inadequate aPTT Monitoring
Check aPTT at 3,6,12, and 24 hours initially, then daily. Target 50-75 seconds. Subtherapeutic levels increase rebound ischemia risk; supratherapeutic levels increase bleeding 3.
3. Premature Discontinuation
Continue heparin for minimum 48 hours. Early discontinuation (before 48 hours) increases reinfarction risk due to rebound hypercoagulability 3.
4. Wrong Anticoagulant Choice for Specific Scenarios
- If patient received enoxaparin prehospital and last dose was <8 hours ago, do not give additional enoxaparin 1
- Do not use fondaparinux as sole anticoagulant if PCI is planned - it increases catheter thrombosis risk 1, 3
Alternative Anticoagulation Options
While UFH is standard, the guidelines also recognize enoxaparin as an alternative 1:
Enoxaparin with fibrinolytic therapy:
- Age <75 years: 30 mg IV bolus, then 1 mg/kg subcutaneous every 12 hours (maximum 100 mg first 2 doses)
- Age ≥75 years: No bolus, 0.75 mg/kg subcutaneous every 12 hours (maximum 75 mg first 2 doses)
- CrCl <30 mL/min: 1 mg/kg subcutaneous every 24 hours
The ExTRACT-TIMI 25 trial showed enoxaparin reduced death or recurrent MI compared to UFH (9.9% vs 12.0%) but increased major bleeding (2.1% vs 1.4%) 3. However, UFH remains the standard choice due to its reversibility with protamine and more predictable management in the acute setting 3.
Special Consideration: Planned PCI After Fibrinolysis
If PCI is planned after fibrinolytic therapy, continue UFH infusion and use activated clotting time (ACT) to guide additional dosing in the catheterization laboratory 1. The ASSENT-4 PCI trial demonstrated that routine facilitated PCI (tenecteplase followed by planned PCI within 1-3 hours) resulted in worse outcomes and is not recommended 2. However, rescue PCI for failed fibrinolysis or delayed PCI (>24 hours) for high-risk anatomy remains appropriate with continued anticoagulation.